SCHEMBL4932124

SCHEMBL4932124

COc1cccc(Nc2cc(Cl)ccc2[N+](=O)[O-])c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.63
SMN1; SMN2 Q16637 2/20 0.63
ALPG P10696 1/20 0.63
TDP1 Q9NUW8 1/20 0.63
MEN1 O00255 2/20 0.61
KMT2A Q03164 2/20 0.61
HPGD P15428 2/20 0.59
FBP1 P09467 4/20 0.57
PKM P14618 2/20 0.55
POLB P06746 1/20 0.55
NCOA1 Q15788 1/20 0.55
NCOA3 Q9Y6Q9 1/20 0.55
LMNA P02545 2/20 0.54
AKR1B10 O60218 2/20 0.53
AKR1B1 P15121 2/20 0.53
AKR1C4 P17516 2/20 0.53
AKR1C3 P42330 2/20 0.53
AKR1C2 P52895 2/20 0.53
AKR1C1 Q04828 2/20 0.53
L3MBTL1 Q9Y468 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2324743 0.90 AKR1C3 (0.60) MAPTSMN1; SMN2ALPGTDP1MEN1
SCHEMBL11901725 0.86 MEN1 (0.62) MAPTMEN1KMT2AHPGDFBP1
SCHEMBL4744863 0.85 MAPT (0.64) MAPTSMN1; SMN2ALPGTDP1MEN1
SCHEMBL8886340 0.85 L3MBTL1 (0.61) MAPTSMN1; SMN2ALPGTDP1PKM
SCHEMBL19781761 0.85 MEN1 (0.61) MAPTMEN1KMT2AHPGDFBP1
SCHEMBL2330420 0.85 MAPT (0.62) MAPTMEN1KMT2AHPGDFBP1
SCHEMBL4947225 0.84 MAPT (0.67) MAPTSMN1; SMN2TDP1MEN1KMT2A
SCHEMBL2328384 0.83 MAPT (0.58) MAPTSMN1; SMN2ALPGTDP1MEN1
SCHEMBL2327163 0.83 L3MBTL1 (0.56) MAPTSMN1; SMN2ALPGTDP1MEN1
SCHEMBL26906360 0.81 MAPT (0.75) MAPTSMN1; SMN2TDP1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080021069-A1 Receptor Function Regulating Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 US disclosed
EP-1810677-A1 RECEPTOR FUNCTION REGULATING AGENT Takeda Pharmaceutical Company Limited (JP) 2007-07-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021069-A1 Receptor Function Regulating Agent GPR119, INSR, GPR65 MAPT 4574/4885SMN1; SMN2 4521/4885ALPG 3964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.